No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three 'field-practice' cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors / Pusceddu S.; Barretta F.; Trama A.; Botta L.; Milione M.; Buzzoni R.; De Braud F.; Mazzaferro V.; Pastorino U.; Seregni E.; Mariani L.; Gatta G.; Di Bartolomeo M.; Femia D.; Prinzi N.; Coppa J.; Panzuto F.; Antonuzzo L.; Bajetta E.; Pia Brizzi M.; Campana D.; Catena L.; Comber H.; Dwane F.; Fazio N.; Faggiano A.; Giuffrida D.; Henau K.; Ibrahim T.; Marconcini R.; Massironi S.; Zakelj M.P.; Spada F.; Tafuto S.; Van Eycken E.; Van Der Zwan J.M.; Zagar T.; Giacomelli L.; Miceli R.; Francesca A.; Alberto B.; Rossana B.; Nicole B.; Sara C.; Carolina C.; Federica C.; Carlo C.; Francesca C.; Marilina D.; Vittoria D.M.; Chiara D.D.; Paola E.; Anna L.S.; Gabriele L.; Giuseppe L.R.; Federico N.; Alessandra R.; Vittorio P.; Paola R.; Maria R.; Sabine S.; Martina T.; Boukje V.D.; Otto V.; Claudio V.. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - ELETTRONICO. - 25:(2018), pp. 607-618. [10.1530/ERC-17-0489]

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors

Pusceddu S.;Trama A.;Di Bartolomeo M.;Antonuzzo L.
Writing – Original Draft Preparation
;
Faggiano A.;Giuffrida D.;Spada F.;Marilina D.;Otto V.;
2018

Abstract

No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three 'field-practice' cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.
2018
25
607
618
Pusceddu S.; Barretta F.; Trama A.; Botta L.; Milione M.; Buzzoni R.; De Braud F.; Mazzaferro V.; Pastorino U.; Seregni E.; Mariani L.; Gatta G.; Di B...espandi
File in questo prodotto:
File Dimensione Formato  
1479-6821-ERC-17-0489.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1193604
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact